Back to Search Start Over

Novel MLL/KMT2A-MON2 fusion in a child with therapy-related acute myeloid leukemia after treatment for acute promyelocytic leukemia.

Authors :
Gong Y
Wang M
Shen H
Chen Y
Cen J
Yin X
Yao L
Source :
Molecular carcinogenesis [Mol Carcinog] 2021 Nov; Vol. 60 (11), pp. 721-725. Date of Electronic Publication: 2021 Jul 08.
Publication Year :
2021

Abstract

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), which is characterized by the reciprocal t (15;17) (q24; q21) translocation, resulting in PML-RARA gene fusion. Therapy-related AML (t-AML) is a serious complication after cytotoxic and/or radiation therapy in many malignant diseases. In this report, MLL/KMT2A-MON2, with balanced chromosomal translocation t (11;12) (q23; q14), was identified as a novel fusion in a child transformed to t-AML after successful treatment of APL. This study emphasized that clinical monitoring with an integrated laboratory approach is essential for the diagnosis and treatment of t-AML.<br /> (© 2021 Wiley Periodicals LLC.)

Details

Language :
English
ISSN :
1098-2744
Volume :
60
Issue :
11
Database :
MEDLINE
Journal :
Molecular carcinogenesis
Publication Type :
Academic Journal
Accession number :
34236108
Full Text :
https://doi.org/10.1002/mc.23333